Mirna Golemović

453 total citations
25 papers, 353 citations indexed

About

Mirna Golemović is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Mirna Golemović has authored 25 papers receiving a total of 353 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Hematology, 8 papers in Molecular Biology and 7 papers in Genetics. Recurrent topics in Mirna Golemović's work include Acute Myeloid Leukemia Research (8 papers), Chronic Myeloid Leukemia Treatments (7 papers) and Retinoids in leukemia and cellular processes (7 papers). Mirna Golemović is often cited by papers focused on Acute Myeloid Leukemia Research (8 papers), Chronic Myeloid Leukemia Treatments (7 papers) and Retinoids in leukemia and cellular processes (7 papers). Mirna Golemović collaborates with scholars based in Croatia, United States and Switzerland. Mirna Golemović's co-authors include Srđan Verstovšek, Francis J. Giles, Hagop M. Kantarjian, Miloslav Beran, Jörge E. Cortes, Margaret Dugan, Leila Alland, Paul W. Manley, Tong Sun and Ralph B. Arlinghaus and has published in prestigious journals such as Blood, Cancer and Clinical Cancer Research.

In The Last Decade

Mirna Golemović

25 papers receiving 344 citations

Peers

Mirna Golemović

HEMAT

GENET

RHEUM

ONCOL

Emilia Scalzulli Italy

Dushyant Verma United States

Arta Dreimane Sweden

Daigo Akahane Japan

Jimmie H. Harvey United States

Patrizia Guglielmo Italy

Chandrakala Shanmukhaiah India

Hayri Özsan Türkiye

H. L. Seewann Austria

Elisa Zuffa Italy

Emilia Scalzulli Italy

Mirna Golemović

271 ×1.2

HEMAT

159 ×0.9

GENET

52 ×0.4

RHEUM

120 ×1.4

90 ×1.6

ONCOL

Citations per year, relative to Mirna Golemović Mirna Golemović (= 1×) peers Emilia Scalzulli

Countries citing papers authored by Mirna Golemović

Since Specialization

Citations

This map shows the geographic impact of Mirna Golemović's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mirna Golemović with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mirna Golemović more than expected).

Fields of papers citing papers by Mirna Golemović

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mirna Golemović. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mirna Golemović. The network helps show where Mirna Golemović may publish in the future.

Co-authorship network of co-authors of Mirna Golemović

This figure shows the co-authorship network connecting the top 25 collaborators of Mirna Golemović. A scholar is included among the top collaborators of Mirna Golemović based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mirna Golemović. Mirna Golemović is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Golemović, Mirna, et al.. (2022). Ten-year experience with cryopreserved vascular allografts in the Croatian Cardiovascular Tissue Bank. Cell and Tissue Banking. 23(4). 807–824. 7 indexed citations

Golemović, Mirna, et al.. (2022). Cryopreserved human heart valve allografts: a ten-year single centre experience. Cell and Tissue Banking. 24(2). 401–416. 3 indexed citations

Petrunić, Mladen, et al.. (2019). Recurrent Aortic Infections Due to Unrecognized Aorto-Enteric Fistula. Annals of Vascular Surgery. 63. 455.e11–455.e15. 2 indexed citations

Golemović, Mirna, et al.. (2019). Colony-forming unitassay as a potency test for hematopoietic stem/progenitor cell products. 2(2). 51–56. 3 indexed citations

Golemović, Mirna. (2018). ADVANCED THERAPY MEDICINAL PRODUCTS – AN OVERVIEW. 1(1). 21–25. 29 indexed citations

Golemović, Mirna, et al.. (2018). Comparative Analysis of Biological and Functional Properties of Bone Marrow Mesenchymal Stromal Cells Expanded in Media with Different Platelet Lysate Content. Cells Tissues Organs. 205(4). 226–239. 5 indexed citations

Mazić, Sanja, et al.. (2013). Treatment of chronic GVHD with extracorporeal photochemotherapy. Transfusion and Apheresis Science. 48(2). 193–194. 2 indexed citations

Golemović, Mirna, et al.. (2013). Cardiovascular tissue banking in Croatia. Journal of Cardiothoracic Surgery. 8(S1). 1 indexed citations

Golemović, Mirna, Alfonso Quintás‐Cardama, Taghi Manshouri, et al.. (2009). MER1, a novel organic arsenic derivative, has potent PML-RARα- independent cytotoxic activity against leukemia cells. Investigational New Drugs. 28(4). 402–412. 13 indexed citations

10.

Oršolić, Nada, Mirna Golemović, Alfonso Quintás-Cardama, et al.. (2006). Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells. Cancer Science. 97(9). 952–960. 16 indexed citations

11.

Verstovšek, Srđan, Mirna Golemović, Hagop M. Kantarjian, et al.. (2005). AMN107, a novel aminopyrimidine inhibitor of p190 Bcr‐Abl activation and of in vitro proliferation of Philadelphia‐positive acute lymphoblastic leukemia cells. Cancer. 104(6). 1230–1236. 55 indexed citations

12.

Golemović, Mirna, Srđan Verstovšek, Francis J. Giles, et al.. (2005). AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has In vitro Activity against Imatinib-Resistant Chronic Myeloid Leukemia. Clinical Cancer Research. 11(13). 4941–4947. 162 indexed citations

13.

Golemović, Mirna, et al.. (2005). IgH and TCRγ gene rearrangements, cyclin A1 and HOXA9 gene expression in biphenotypic acute leukemias. Leukemia Research. 30(2). 211–221. 4 indexed citations

14.

Golemović, Mirna, et al.. (2005). IgH and TCRgamma Gene Rearrangements, Cyclin A1 and HOXA9 Gene Expression in Biphenotypic Acute Leukemias.. Blood. 106(11). 4472–4472. 2 indexed citations

15.

Oršolić, Nada, Francis J. Giles, Henriette Gourdeau, et al.. (2004). Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation. British Journal of Haematology. 124(6). 727–738. 6 indexed citations

16.

Golemović, Mirna, Francis J. Giles, Miloslav Beran, et al.. (2004). AMN107, a Novel Aminopyrimidine Inhibitor of BCR-ABL, Has Pre-Clinical Activity Against Imatinib Mesylate-Resistant Chronic Myeloid Leukemia (CML).. Blood. 104(11). 1983–1983. 2 indexed citations

17.

Cheng, Xiaodong, Mirna Golemović, Francis J. Giles, et al.. (2004). Organic Arsenic Lipid Derivatives Are More Potent and Less Toxic Than Inorganic Arsenic Trioxide in Preclinical Testing.. Blood. 104(11). 1803–1803. 4 indexed citations

18.

Duzkale, Hatice, Iman Jilani, Nada Oršolić, et al.. (2003). In vitro activity of dimethylarsinic acid against human leukemia and multiple myeloma cell lines. Cancer Chemotherapy and Pharmacology. 51(5). 427–432. 16 indexed citations

19.

Golemović, Mirna, Hagop Kantarjian, Nada Oršolić, et al.. (2003). Development of an organic arsenic derivative as a therapy for leukaemia. 2 indexed citations

20.

Sučić, Mirna, Branka Užarević, Renata Zadro, et al.. (1999). Double Immunoenzymatic APAAP Staining for the Detection of Leukemia-Associated Immunophenotypes. Journal of Hematotherapy & Stem Cell Research. 8(6). 635–643. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact